European Medical Solutions

DB:AS0 Stock Report

Market Cap: €26.8m

European Medical Solutions Past Earnings Performance

Past criteria checks 0/6

European Medical Solutions has been growing earnings at an average annual rate of 52.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 51.4% per year.

Key information

52.3%

Earnings growth rate

84.4%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate51.4%
Return on equity-10.6%
Net Margin-2.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How European Medical Solutions makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:AS0 Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2444-1130
31 Mar 2443-1130
31 Dec 2343-1120
30 Sep 2341-1120
30 Jun 2340-1120
31 Mar 2338-3120
31 Dec 2237-6110
30 Sep 2266-7190
30 Jun 2257-4170
31 Mar 2248-2140
31 Dec 21380110
30 Sep 210210
30 Jun 210010
31 Mar 210-110
31 Dec 200-110
30 Sep 200-524
30 Jun 200-927
31 Mar 201-12310
31 Dec 191-16414
30 Sep 191-16313
30 Jun 191-17313
31 Mar 191-16312
31 Dec 181-14310
30 Sep 181-12310
30 Jun 181-1139
31 Mar 181-11210
31 Dec 171-12211
30 Sep 171-12211
30 Jun 172-12212
31 Mar 172-12212
31 Dec 162-12212
30 Sep 161-12211
30 Jun 160-12111
31 Mar 160-1019
31 Dec 150-817
31 Dec 140-413
31 Dec 130-212

Quality Earnings: AS0 is currently unprofitable.

Growing Profit Margin: AS0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AS0 is unprofitable, but has reduced losses over the past 5 years at a rate of 52.3% per year.

Accelerating Growth: Unable to compare AS0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AS0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: AS0 has a negative Return on Equity (-10.58%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:52
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

European Medical Solutions is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hugo SolvetBryan Garnier & Co
Andrew SmithEdison Investment Research
Stephanie LefebvreGilbert Dupont